Lexicon Pharmaceuticals (LXRX) Retained Earnings (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) reported Retained Earnings of -$2.0 billion for Q1 2026, down 1.31% year-over-year from -$2.0 billion in Q1 2025, and little changed quarter-over-quarter from -$2.0 billion in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Retained Earnings (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has 17 years of Retained Earnings data on file, last reported at -$2.0 billion in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$2.0 billion, down 1.31% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.0 billion (down 1.31% YoY), and the FY2025 annual result was -$2.0 billion, down 2.56% from the prior year.
- Retained Earnings was little changed at -$2.0 billion in Q1 2026 per LXRX's latest filing, from -$2.0 billion in the prior quarter.
- Over five years, Retained Earnings peaked at $349000.0 in Q3 2024 and troughed at -$2.0 billion in Q1 2026.
- A 5-year average of -$1.2 billion and a median of -$1.7 billion in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings plunged 30225140.0% in 2022, then soared 100.02% in 2024.
- A 5-year view of Retained Earnings shows it stood at -$1.6 billion in 2022, then declined by 11.14% to -$1.8 billion in 2023, then slipped by 11.34% to -$2.0 billion in 2024, then decreased by 2.56% to -$2.0 billion in 2025, then declined by 0.05% to -$2.0 billion in 2026.
- Business Quant data shows LXRX's Retained Earnings at -$2.0 billion in Q1 2026, -$2.0 billion in Q4 2025, and -$2.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | Lexicon Pharmaceuticals | 804.48 Mn | 633.82 Mn | 20.99 Mn | -2.02 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.02 Bn |
| Dec 31, 2025 | -2.02 Bn |
| Sep 30, 2025 | -2.00 Bn |
| Jun 30, 2025 | -14,000.00 |
| Mar 31, 2025 | -1.99 Bn |
| Dec 31, 2024 | -1.97 Bn |
| Sep 30, 2024 | 349,000.00 |
| Jun 30, 2024 | -1.87 Bn |
| Mar 31, 2024 | -1.82 Bn |
| Dec 31, 2023 | -1.77 Bn |
| Sep 30, 2023 | -1.72 Bn |
| Jun 30, 2023 | -100,000.00 |
| Mar 31, 2023 | -163,000.00 |
| Dec 31, 2022 | -1.59 Bn |
| Sep 30, 2022 | -491,000.00 |
| Jun 30, 2022 | -150,000.00 |
| Mar 31, 2022 | -1.51 Bn |
| Dec 31, 2021 | -1.49 Bn |
| Sep 30, 2021 | -1.46 Bn |
| Jun 30, 2021 | -1.44 Bn |